|
|
Other links at Articles > Business of Medicine |
| 1. |
Bivalirudin "Nonapprovable" for ACUITY Indication
|
|
|
The US FDA has issued a "not-approvable" letter to the Medicines Company for an additional dosing regimen of the drug covering upstream treatment of ACS initiated in the emergency department, based on the ACUITY trial. Heartwire
|
| 2. |
U.S. Democratic Lawmakers Blast CDC on FEMA Trailers
|
|
|
The U.S. Centers for Disease Control and Prevention bungled by not checking sooner for formaldehyde in trailers use to house victims of hurricanes Katrina and Rita, Democrats on a House of Representatives Committee said on Wednesday. Reuters Health Information
|
| 4. |
Survey Suggests U.S. Research Misconduct Is Common
|
|
|
Research misconduct at U.S. institutions may be more common than previously suspected, with 9 percent of scientists saying in a new survey that they personally had seen fabrication, falsification or plagiarism. Reuters Health Information
|
| 5. |
Cases from AHRQ WebM&M: The Inside of a Time Out
|
|
|
The Joint Commission Universal Protocol requires a final "time out" just prior to the surgery or procedure regardless of where it is being performed. Are you taking the time? Agency for Healthcare Research and Quality (AHRQ)
|
|
|
